April 17, 2024
Medscape highlighted University of Cincinnati research published in JAMA Dermatology that found skin adverse events were rare following immunotherapy treatments for certain skin cancers.
April 4, 2024
Clinical research conducted at the University of Cincinnati College of Medicine and UC Health played a role in the U.S. Food and Drug Administration's March 26 approval of WINREVAIR™ (sotatercept-csrk) for the treatment of pulmonary arterial hypertension (PAH) in adults.
May 15, 2024
The University of Cincinnati’s Yasmin Aziz will present research at the European Stroke Organisation Conference that found severe ischemic strokes with the most severe damage are rare in the total stroke patient population.
May 22, 2024
TCT MD included comments from the University of Cincinnati's Eva Mistry in a story recapping trial data presented at the European Stroke Organisation Conference that found clot-busting drug tenectaplase is becoming a first-choice treatment in certain situations.
August 10, 2022
University of Cincinnati researchers Jason Gardner and Matthew Robson are studying whether targeting an inflammation pathway that affects burns and traumatic brain injuries can be an effective treatment for both conditions.
May 10, 2022
Research from the University of Cincinnati shows daily blueberry supplementation for certain middle-aged populations may lower the chances of developing late-life dementia.
June 4, 2022
The University of Cincinnati's Thomas Herzog, MD, is presenting a poster describing a new immunotherapy trial for platinum-resistant ovarian cancer, called ARTISTRY-7, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
August 24, 2022
Radiology Business highlighted the research of the University of Cincinnati's Prashanth Ravi and Frank Rybicki that found an in-house 3D print shop saved almost $3,000 per patient in operating-room costs thanks to shortened procedure times.
October 13, 2022
The University of Cincinnati's Jeffrey Strawn, MD, is senior author of a new editorial in JAMA discussing new recommendations that children and adolescents ages 8 to 18 should be screened for anxiety disorders.
October 20, 2022
New research out of the University of Cincinnati shows that a course of a hepatitis B vaccine provides complete protection for people with HIV. The UC research shows that a three-dose course of the hepatitis B vaccine HEPLISAV-B provides complete protection for people living with HIV who have never been vaccinated against or exposed to the hepatitis B virus (HBV).